We are pleased to announce our newest paper in Cancers MDPI is now published online!
This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01) in ovarian cancer therapy, and shows how selective antagonization of TSP-1:CD47 axis is a new powerful way of activating anti-tumor immunity.
We believe our innovative technology to be a safer and effective approach with the potential to treat multiple indications of solid tumors.
More: read the article in Cancers (DOI: 10.3390/cancers13195019)
